Coherus Biosciences Inc [CHRS] stock is trading at $0.78, down -4.44%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CHRS shares have gain 16.24% over the last week, with a monthly amount drifted -21.35%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Coherus Biosciences Inc [NASDAQ: CHRS] stock has seen the most recent analyst activity on August 16, 2024, when UBS downgraded its rating to a Neutral and also revised its price target to $1.50 from $4. Previously, Robert W. Baird started tracking the stock with Outperform rating on November 17, 2023, and set its price target to $11. On November 08, 2023, downgrade downgraded it’s rating to Hold. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $12 on July 24, 2023. Truist initiated its recommendation with a Buy and recommended $24 as its price target on May 01, 2023. UBS upgraded its rating to Buy for this stock on March 28, 2023, but kept the price target unchanged to $11. In a note dated June 14, 2022, UBS initiated an Neutral rating and provided a target price of $7 on this stock.
Coherus Biosciences Inc [CHRS] stock has fluctuated between $0.66 and $3.70 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Coherus Biosciences Inc [NASDAQ: CHRS] shares were valued at $0.78 at the most recent close of the market. An investor can expect a potential return of 1053.85% based on the average CHRS price forecast.
Analyzing the CHRS fundamentals
Coherus Biosciences Inc [NASDAQ:CHRS] reported sales of 304.34M for the trailing twelve months, which represents a drop of -5.09%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -0.43%, Pretax Profit Margin comes in at -0.0%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is 0.0 and Total Capital is -0.63. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7531 points at the first support level, and at 0.7273 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8273, and for the 2nd resistance point, it is at 0.8757.
Ratios To Look Out For
For context, Coherus Biosciences Inc’s Current Ratio is 1.25. As well, the Quick Ratio is 1.09, while the Cash Ratio is 0.33. Considering the valuation of this stock, the price to sales ratio is 0.29.
Transactions by insiders
Recent insider trading involved Lanfear Dennis M, President & CEO, that happened on Nov 22 ’23 when 0.22 million shares were sold.
